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Abstract
The DNA mismatch repair system (MMR) maintains genome stability through recognition and repair of single-base
mismatches and small insertion-deletion loops. Inactivation of the MMR pathway causes microsatellite instability and
the accumulation of genomic mutations that can cause or contribute to cancer. In fact, 10-20% of certain solid and
hematologic cancers are MMR-deficient. MMR-deficient cancers do not respond to some standard of care
chemotherapeutics because of presumed increased tolerance of DNA damage, highlighting the need for novel
therapeutic drugs. Toward this goal, we generated isogenic cancer cell lines for direct comparison of MMR-proficient
and MMR-deficient cells. We engineered NCI-H23 lung adenocarcinoma cells to contain a doxycycline-inducible
shRNA designed to suppress the expression of the mismatch repair gene MLH1, and compared single cell subclones
that were uninduced (MLH1-proficient) versus induced for the MLH1 shRNA (MLH1-deficient). Here we present the
characterization of these MMR-inducible cell lines and validate a novel class of rhodium metalloinsertor compounds
that differentially inhibit the proliferation of MMR-deficient cancer cells.
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Introduction
Genome instability is a hallmark of cancer cells and can lead
to numerical or structural changes to chromosomes
(chromosome instability, or CIN), or nucleotide mismatch repair
(MMR) deficiency (MIN) [1]. While CIN can result from loss of
function of a number of cellular pathways, MIN results
specifically from defects in the MMR system and is identifiable
by the gain or loss of mono-, di- or tri-nucleotide repeat
sequences, referred to as microsatellite instability (MSI)
(reviewed in 2). Replication errors such as polymerase
slippage generate small insertion-deletion loops (IDLs) or
single base mismatches in the DNA. DNA damage can also
modify bases to cause mismatches. In human cells that are
MMR-proficient, heterodimers that contain the bacterial MutS
homolog MSH2 bind a mismatch, and then heterodimers that
contain the bacterial MutL homolog MLH1 associate with the
protein:DNA complex to mediate the recruitment of repair
factors that excise the mismatch and restore the correct DNA
sequence. MMR-deficient cells are unable to correct
mismatches, resulting in incorporation of errors into the DNA
template and a mutator phenotype.
MMR deficiency is strongly linked with cancer. Germ line
mutation of MMR genes, particularly MLH1 or MSH2, is the
basis of hereditary non-polyposis colorectal cancer (HNPCC),
or Lynch syndrome, which confers susceptibility to colorectal
cancer but also to other specific cancer types including
endometrial and ovarian cancer (reviewed in 3,4). Mutation or
hypermethylation of MMR genes in somatic cells is associated
with approximately 15% of sporadic colorectal cancers, as well
as 10-15% of ovarian, endometrial and gastric cancers
(reviewed in 5). MMR deficiency and MSI have also been
identified in up to 20% of leukemias in patients that relapse, or
that develop the disease as a consequence of prior
chemotherapy [6].
MMR deficiency and MSI also occur in primary lung cancer
associated with smoking or exposure to chromium [7-9].
Cancers with MSI have been reported to be resistant to several
standard-of-care chemotherapeutic agents, such as the
antimetabolite 5-fluorouracil (5-FU), the platinum compounds
cisplatin and carboplatin, the alkylating drug temozolomide,
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and the topoisomerase inhibitor etoposide [10]. Inactivation of
the MMR pathway may allow cells to tolerate certain types of
DNA damage without initiating a pathway of programmed cell
death [11].
One challenge to identifying therapies for MMR-deficient
cancers is that the molecular targets and clinical phenotypes
resulting from inactivation of MMR genes are variable. MMR
deficiency can lead to frameshift mutations in genes that
contain repeat sequences in the DNA, and at least 30 genes
have been identified as potential targets of MSI, including the
oncogenes BRAF and KRAS, and the DNA damage response
genes MRE11, BRCA1 and ATR [12,13]. Efforts to identify
novel therapeutic targets that exhibit synthetic lethality with
MMR-deficient cancer cells have revealed variability in genetic
targets with loss of function of MLH1 or MSH2 [14]. Together,
these observations support the idea that cancers with MSI
represent a multifaceted, heterogeneous set of diseases. In
consideration of the complexity of MSI tumors, we have
previously proposed targeting the end phenotype or “state” of
mismatch repair deficiency itself [15,16].
In the current effort described here, our goal was to develop
tools to enable studies of induced mismatch repair deficiency.
We describe a completely isogenic cell line system in which
expression of the MMR gene MLH1 can be switched on or off
using shRNA. As our model system we used the lung
adenocarcinoma NCI-H23, a cell line selected based on
relatively high levels of MLH1 that could be reversibly
inactivated by shRNA. In this study, we induce MMR deficiency
in the NCI-H23 cell line system and demonstrate that this
results in MSI and increased resistance to DNA damaging
agents. As a potential step toward developing a therapeutic
that targets the end “state” of MMR deficiency, we also use this
cell line system to further validate a novel class of metal
complexes that target DNA mismatches.
Materials and Methods
Short hairpin RNA (shRNA)
Sequences predicted to knock down expression of the MLH1
or MSH2 genes were designed using BLOCK-IT RNAi
Designer (Life Technologies). Four independent sequences for
each gene were chosen as candidate shRNA triggers as
indicated below (numbering indicates position on the cDNA).








The method used for construction of the shRNA cassettes
has been described in detail elsewhere [17]. Briefly, shRNA
sense-loop-antisense constructs of these sequences were
generated by PCR, using TTCATGAGA as the loop sequence.
The final PCR product, which contained the sense-loop-
antisense shRNA sequences flanked by the attB1 site and tH1
promoter on the 5’ end, and a termination signal and the attB2
site on the 3’ end, was then cloned into the Gateway vector
pDONR (Life Technologies). Gateway recombination
techniques were then used to transfer the shRNA cassettes
into Gateway-compatible lentiviral destination vectors pLV736G
or pLV739G.
Lentiviral stocks were prepared as described [17]. 293-
METR cells [18] were transfected with a pLV736G or pLV739G
vector that contained an individual shRNA cassette, together
with plasmids containing the Gag/Pol, Rev, and Env genes.
After overnight incubation, the supernatant was collected,
filtered, concentrated by ultracentrifugation and stored at
-80°C.
Cell line generation
NCI-H23 cells obtained from the American Type Culture
Collection (ATCC) were grown in RPMI media with 10% fetal
bovine serum. For lentiviral transduction, NCI-H23 cells were
seeded at 2 x 104 cells per ml in 12-well plates and incubated
overnight. Media was aspirated from the cells and replaced
with Opti-MEM media (Life Technologies) that contained 10
µg/ml Diethylaminoethyl-Dextran (GE Healthcare Life
Sciences) and 1-5 x 106 transduction units per milliliter (TU/ml)
of lentivirus. Cells were transduced with lentivirus containing
MLH1 shRNA or MSH2 shRNA. Plates were incubated
overnight, and then media containing lentivirus was aspirated
off and replaced with fresh RPMI media. After 1-3 days (d),
cells were expanded to 6-well plates and grown in the
presence of selection agent (250 µg/ml G418 for MLH1 and 2.5
µg/ml puromycin for MSH2). 500ng/ml doxycycline (Sigma-
Aldrich) was added to the cells to induce expression of the
shRNA.
Cells grown under selection and with shRNA induced for at
least 2 months were plated to 96-well plates at a density of 0.3
cells per well to select for single cell subclones. Single cell
subclones were expanded and maintained under selection
conditions. Uninduced cells used for comparison to the induced
subclones were obtained by culturing the subclones in the
absence of doxycycline for at least one week.
Antibodies and western blots
Protein lysates were prepared in lysis buffer (50mM HEPES,
1% Triton X-100, 150mM NaCl, 1mM EGTA, 10% glycerol,
1mM dithiothreitol) to which phosphatase and protease
inhibitors (20mM -glycerophosphate, 100mM sodium fluoride,
0.5mM phenylmethylsulfonyl fluoride, 0.1mM sodium
orthovanadate, 10 µg/ml leupeptin) were added. Lysates were
cleared by centrifugation and then analyzed by SDS-PAGE on
4-12% Bis-Tris gels (Life Technologies) followed by
immunoblotting. Primary antibodies used were against MLH1
(Becton Dickinson #551091), MSH2 (Becton Dickinson
#556349), GAPDH (Abcam #ab9484), phosphorylated histone
H2AX (Millipore #05-636) or tubulin (Cell Signaling #2148).
Primary antibodies were detected with secondary antibodies
conjugated to IRDye700 or IRDye800 (LiCOR) and visualized
with the LiCOR Odyssey. Each western blot experiment was
carried out at least twice, on independent days. Representative
data from a single experiment are shown.
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DNA fragment analysis
Genomic DNA from the NCI-H23 subclones was prepared
using a DNeasy kit (Qiagen). Multiplex PCR reactions were
carried out according to the MSI Analysis System, Version 2.1
(Promega). PCR products were analyzed on an ABI 3130
sequencer, and then the data were analyzed using
GeneMapper software (Life Technologies). Subclones that
exhibited MSI for at least one marker in the first experiment
were retested in an independent experiment to confirm the
results.
Cell viability assays
Cells grown in the absence or presence of doxycycline were
plated at 2000-5000 cells per well in 96-well plates and allowed
to incubate overnight. Cells were then treated with compounds
in a dose response for 4d. Cell viability was assessed using a
Cell Titer-Glo assay (Promega) for ATP metabolism. Cell
viability assays were performed in duplicate in at least 3
independent experiments. Representative data from one such
experiment are shown.
Phase contrast imaging of cells during the proliferation
experiments was carried out using an IncuCyte with a 20X
objective (Essen BioScience).
Colony forming assays were also used to test cell viability
following compound treatment. Cells grown in the absence or
presence of doxycycline were plated at 500-2000 cells per well
of a 6-well plate and allowed to incubate overnight. Cells were
treated with compounds in a dose response for 24 hours (h),
and then media was aspirated and replaced with fresh media
that did not contain compound. Colonies were visualized with
crystal violet stain at 10-12d.
Senescence associated beta-galactosidase (SA--gal)
production was assessed using a histochemical stain for beta-
galactosidase activity at pH6.0 (Sigma-Aldrich). Cells were
untreated or treated with compounds as indicated for 3d, and
then cells were fixed, stained for SA--gal and imaged using a
Zeiss Axio inverted microscope equipped with a color camera.
Statistical analysis
For the cell viability assays, paired t tests were used to
compare half maximal inhibitory (IC50) or median lethal dose
(LD50) values from multiple experiments and determine p
values. P values equal to or less than 0.05 were considered
statistically significant. Statistical analysis was done with Graph
Pad Prism software.
Microarray analysis
Total RNA was prepared from duplicate samples of cells in
log phase of growth, using an RNeasy mini kit (Qiagen).
Sample integrity was assessed on a BioAnalyzer. Cy3- and
Cy5-labeled RNA was prepared from 200ng total RNA per
sample, and then hybridized to Human Whole Genome Arrays
(Agilent Technologies) according to the Agilent Two-Color
Microarray-Based Gene Expression Analysis Protocol. Data
were analyzed in Rosetta Resolver.
Chemical compounds
Synthesis of [Rh (HDPA)2chrysi]3+ and [Rh(DIP)2chrysi]3+
have been described [19,20]. The synthesis of [Rh(DPE)(phen)
(chrysi)]3+ was recently reported [21]. Cisplatin, doxorubicin,
etoposide, 6-thioguanine and temozolomide were obtained
from Sigma-Aldrich and dissolved in DMSO or water. The
CDK4/6 inhibitor PD-0332991 [22], used as a positive control
for senescence assays, was synthesized according to
published methods.
Results
Inhibition of MLH1 by shRNA reduces MLH1 protein
levels
The NCI-H23 lung adenocarcinoma cell line is proficient for
mismatch repair and contains relatively high levels of the MMR
proteins MLH1 and MSH2 [23]. With the goal of generating a
matched system that induces MMR deficiency and allows direct
comparison to MMR-proficient cells, we tested whether
expression of these MMR proteins could be downregulated by
shRNA. NCI-H23 cells were transduced with lentivirus
containing inducible shRNA to MLH1 or MSH2, and cells that
stably integrated the construct into the genome were selected
and expanded. Under normal growth conditions, the integrated
shRNA was not active and the MMR proteins continued to be
expressed. Expression of the shRNA was regulated by treating
the cells with doxycycline. When the shRNA was induced,
protein lysates from cells that contained any of the four shRNA
constructs against MLH1 demonstrated near complete (>90%)
inhibition of the MLH1 protein (Figure S1). In contrast, the
MSH2 protein was only partially decreased after induction of
any of the four MSH2 shRNA constructs in NCI-H23 cells
(Figure S1) and these cells were not further characterized.
Because of the potential for variability of shRNA expression
within a cell population, we isolated and characterized single
cell subclones from NCI-H23 cells transduced with one of the
shRNA constructs, MLH1 928. Cells were grown in the
presence of doxycycline to induce the MLH1 shRNA for at least
one month, and then plated for single cells which were
expanded into colonies that were maintained in inducing
conditions. MMR protein levels were then re-assessed by
immunoblotting. The NCI-H23 subclones that expressed MLH1
shRNA consistently reduced the levels of MLH1 protein >90%,
without affecting the levels of MSH2 protein (Figure 1).
Downregulation of MLH1 induces microsatellite
instability
We selected at least 20 subclones from NCI-H23 cells that
expressed MLH1 shRNA to test for MSI. Genomic DNA was
prepared from parental NCI-H23 cells and from each subclone,
and then multiplex PCR was carried out to amplify a standard
panel of microsatellite markers (BAT-26, BAT-25, MONO-27,
NR-21 and NR-24). Fragment sizes of the PCR products were
then analyzed on a DNA sequencer. All of the NCI-H23
subclones showed MSI at the mononucleotide repeat BAT-26
[24], indicated by a shift of 1-3 nucleotides at the locus (Figure
S2). MLH1 deficiency is therefore sufficient to induce MSI. A
number of the subclones also displayed possible MSI at
MLH1-Inducible Cancer Cell Line
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another marker, with independent subclones demonstrating
alteration of different markers (Figure S2). Subclones 4-10 and
4-13, which were obtained by transduction of NCI-H23 cells
with the MLH1 928 shRNA construct, were chosen for
additional phenotypic analysis.
Downregulation of MMR genes by shRNA is reversible
The NCI-H23 single cell subclones were maintained under
growth conditions that continually induced shRNA expression.
To test whether the shRNA-mediated downregulation of MLH1
was reversible, cells from each subclone were split into two
separate cultures, with one culture maintained in the presence
of doxycycline to maintain MLH1 deficiency, and the other
culture grown in the absence of doxycycline to allow MLH1
expression. After one week, protein lysates were prepared from
the cells, and the MLH1 protein level was assessed by
immunoblotting. In the absence of doxycycline, cells from the
4-10 and 4-13 subclones were able to re-express wild-type
levels of MLH1 protein (Figure 2). Not all of the subclones
tested were able to re-express MLH1 protein after growth in the
absence of doxycycline (data not shown), suggesting that the
shRNA in those subclones might be constitutively expressed.
MLH1-deficient NCI-H23 subclones do not display
global changes in gene expression
Microarray analysis was carried out on the NCI-H23 single
cell subclones to test whether downregulation of MLH1 by
shRNA affects the expression of other genes. Cells from
subclones 4-10 and 4-13 were either maintained in the
presence of doxycycline to induce MLH1 shRNA, or grown in
the absence of doxycycline for at least a week to allow re-
expression of MLH1. The parental cell line NCI-H23, either
untreated or treated with doxycycline, was included as a
control. Total RNA was isolated from duplicate samples of
cells, fluorescently labeled, and hybridized to Agilent whole
genome arrays. Gene expression patterns in the uninduced
subclones were similar to those of the parental NCI-H23 cells,
Figure 1.  Induction of MLH1 shRNA decreases MLH1
protein levels.  MLH1 protein levels in NCI-H23 subclones
induced for the MLH1 928 shRNA were compared to MLH1
protein levels in the NCI-H23 parental cells (H23). Protein
lysates were analyzed by SDS-PAGE and immunoblotting for
the MLH1 and MSH2 protein levels. GAPDH was used as a
control for protein loading.
doi: 10.1371/journal.pone.0078726.g001
either untreated or treated with doxycycline (data not shown).
Levels of the MLH1 gene transcript were decreased
approximately three-fold in the 4-10 and 4-13 subclones where
MLH1 shRNA had been induced (Figure S3). A more
widespread gene expression signature associated with MLH1
shRNA induction did not emerge from the data (Figure S3).
MLH1-deficient NCI-H23 subclones exhibit increased
resistance to chemotherapeutic drugs
We next tested whether induced MMR deficiency would
cause resistance to DNA damaging agents. We directly
compared the MMR-deficient NCI-H23 subclones to MMR-
proficient cells from the same subclone that were obtained by
allowing the cells to re-express MLH1. The MMR-deficient and
MMR-proficient subclones were treated with the topoisomerase
inhibitor etoposide or the alkylating agent temozolomide and
cell viability was assessed after 4d (Figure 3A, D). The MMR-
proficient subclones, in which the shRNA was uninduced, did
not show a significant difference in sensitivity to the
compounds compared to parental NCI-H23 cells that were
either untreated or treated with doxycycline (p=0.34) (Figure
S4). For each matched pair of cells (for example, subclone
4-10 uninduced compared to 4-10 induced), the MLH1-deficient
cells were consistently at least two-fold more resistant to these
compounds than the isogenic MLH1-proficient cells, a finding
that is statistically significant (p=0.04 for cells treated with
etoposide, and p=0.01 for cells treated with temozolomide)
(Figure 3A, D). The MLH1-deficient subclones were also more
resistant to the crosslinking agent cisplatin (p=0.02), the purine
analog 6-thioguanine (p=0.05), and another topoisomerase
inhibitor, doxorubicin (p=0.04) (Figure S5). The approximately
two-fold difference in viability of MMR-deficient cells versus
MMR-proficient cells in vitro in response to chemotherapeutic
agents has been reported previously and shown to translate to
drug resistance in vivo (reviewed in 4,10). To confirm that the
Figure 2.  MLH1 shRNA expression is inducible and
reversible.  NCI-H23 subclones 4-10 and 4-13 that were
induced for MLH1 shRNA were split into two cultures, one
maintained in inducing conditions (+ doxycycline) and the other
grown in the absence of doxycycline (-) to allow re-expression
of MLH1. Protein lysates were prepared and analyzed by SDS-
PAGE followed by immunoblotting for expression of the MLH1
protein. Tubulin was used as a control for equal protein loading
across samples.
doi: 10.1371/journal.pone.0078726.g002
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differential effect on viability is due to the presence or absence
of MLH1, we used different shRNA sequences, 362 and 2239,
to inhibit MLH1 expression and then characterized cell
sensitivity to chemotherapeutic drugs. We observed that the
MLH1-deficiency resulting from induction of these independent
shRNA triggers led to a similar increase in resistance to
chemotherapeutic drugs relative to the NCI-H23 cells that
expressed MLH1 (p=0.01) (Figure S6).
To explore the differential sensitivity to the compounds in
more detail, we imaged cells over the 4d treatment period of
the cell viability assay and examined cell count and
morphology. At the 0h time point, the cells are in growth phase
and appear healthy by phase contrast imaging. However by
96h, the differences between the uninduced and induced
subclones were apparent: most of the MLH1-proficient cells
had undergone cell death after treatment with the DNA
damaging agents, whereas the MLH1-deficient cells continued
to proliferate (Figure 3B, E). Treatment with the DNA damaging
agents did not affect MLH1 expression in the uninduced
subclones but did result in increased expression of
phosphorylated histone H2AX, a marker for DNA fragmentation
[25], suggesting that the MLH1-expressing cells had undergone
apoptosis (Figure S7).
We further investigated cell survival following compound
treatment using clonogenic assays. Cells were treated with
etoposide or temozolomide for 24h, and recovery from
compound treatment was assessed by colony formation after
10d. The MLH1-deficient NCI-H23 subclones were more
resistant to compound treatment than the isogenic cells
proficient for MLH1 (Figure 3C, F), showing a significant
difference in the LD50 values (p=0.03 for etoposide, and p=0.04
for temozolomide). Together, these results demonstrate a
differential response to DNA damage that is based solely on
the presence or absence of MLH1.
MLH1-deficient NCI-H23 subclones display increased
sensitivity to rhodium metalloinsertor compounds
We previously described metal complexes that noncovalently
bind DNA mismatches with moderate affinity and high
specificity, due to thermodynamic destabilization of the
mismatched base pairs (reviewed in 26). We initially
demonstrated that this class of compounds preferentially
inhibits the proliferation of MMR-deficient cells, using a
matched HCT-116 colorectal cancer cell line system and a
genetic knockout system [16,19,21]. This earlier work was the
foundation and motivation for the creation of the isogenic cell
lines described in the current study and led us to test whether
rhodium metalloinsertor compounds would also preferentially
inhibit the viability of these cells when MMR deficiency was
induced.
In our inducible cell line system, the rhodium metalloinsertor
compound [Rh(chrysi)(phen)(DPE)]3+ preferentially inhibited the
viability of induced MLH1-deficient NCI-H23 subclones, with at
least a three-fold change in the cellular IC50 in a 4d Cell Titer-
Glo assay relative to the MLH1-proficient subclones (p=0.01)
(Figure 4A, B). Another rhodium metalloinsertor compound,
[Rh(HDPA)2chrysi]3+ also preferentially inhibited proliferation of
MLH1-deficient cells (Figure S8), with a two- to three-fold
change in cellular IC50 values (p=0.02). To confirm that the
difference resulted from MLH1 deficiency rather than an off-
target effect of the shRNA, we used additional, independent
MLH1 shRNA constructs to downregulate MLH1 in NCI-H23
cells and verified that the MLH1-deficient cells were
preferentially sensitive to rhodium metalloinsertor compounds
(p=0.01) (Figure S9). In contrast, a related compound that
exhibits only weak binding to mismatched DNA,
[Rh(DIP)2chrysi]3+ [21] did not display a differential effect on cell
viability of the uninduced and induced NCI-H23 clones (p=0.90)
(Figure S9). Together, our data support the hypothesis that
downregulation of MLH1 increases cell sensitivity to the
rhodium metalloinsertor compounds.
We examined the cellular morphology of the NCI-H23
subclones treated with [Rh(chrysi)(phen)(DPE)]3+ during the
time course of the proliferation assays, using phase contrast
imaging. Cells from the MLH1-proficient and MLH1-deficient
subclones appeared healthy and in growth phase at the 0h
time point. By 96h, the uninduced MLH1-proficient cells had
continued to proliferate but fewer cells appeared to be
undergoing mitosis, suggesting a cell cycle delay or arrest
(Figure 4C). The cells did not appear to be senescent, as
evidenced by lack of production of SA--gal [26] (data not
shown). In contrast, most of the MLH1-deficient cells either
failed to proliferate, or had undergone cell death by 96h (Figure
4C). We verified that this differential effect was due to the
absence or presence of MMR in the cells by assessing MLH1
protein levels in cells treated with rhodium metalloinsertor
compounds (Figure S10). The previously demonstrated effect
of shRNA induction on MLH1 protein expression was not
altered following treatment with the rhodium compounds
(Figure S10).
We also confirmed the increased sensitivity of the MLH1-
deficient NCI-H23 subclones to the rhodium metalloinsertor
compounds using clonogenic assays. After 24h treatment with
[Rh(chrysi)(phen)(DPE)]3+, the MLH1-deficient NCI-H23
subclones formed fewer colonies than the isogenic MLH1-
proficient subclones, exhibiting a significant difference in LD50
values (p=0.01) (Figure 4D). The differential sensitivity of the
MLH1-deficient subclones to the rhodium metalloinsertor
compounds is consistent with the hypothesis that these
compounds exert their effects through binding to DNA
mismatches that are present in MMR-deficient cells.
Discussion
The MMR pathway maintains genome stability by promoting
the recognition and repair of single base mismatches and small
insertion-deletion loops in the DNA that result from replication
errors or DNA damage. Loss of function of the MMR pathway
increases the prevalence of cellular mutations and can cause
or contribute to cancer. The mechanism of carcinogenesis
resulting from inherited MMR deficiency has been well studied,
particularly in colorectal cancer [4,27], and has been modeled
in cell line systems such as HCT-116 O cells, which are MLH1-
deficient but contain an extra copy of Chromosome 2, and
HCT-116 N cells, in which the MLH1 deficiency is
complemented by an extra copy of Chromosome 3 that
MLH1-Inducible Cancer Cell Line
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e78726
Figure 3.  MLH1-deficient NCI-H23 subclones exhibit increased resistance to chemotherapeutic drugs.  NCI-H23 subclones
that were uninduced or induced for MLH1 shRNA were treated with etoposide (A-C) or temozolomide (D-F). (A, D) Cells were
treated with compound at the concentrations indicated, and cell viability was assessed at 4d using a Cell Titer-Glo assay. The
graphs indicate the relative survival for duplicate samples from a single experiment. T tests to compare IC50 values across multiple
experiments determined p values of p=0.04 for cells treated with etoposide, and p=0.01 for cells treated with temozolomide. (B, E)
Phase contrast images of cells at 0h and 96h time points during the cell viability experiment are shown. Cells were treated with 390
µM etoposide (B) or 500 µM temozolomide (E). (C, F) Cells were treated with compound for 24h at the concentrations indicated,
and colony forming ability after compound washout was assessed. The graphs display percent survival at 10d for duplicate samples
of cells treated with etoposide (C) or temozolomide (F). Comparison of the LD50 values across multiple experiments by t-test
determined p values of p=0.03 for cells treated with etoposide, and p=0.04 for cells treated with temozolomide.
doi: 10.1371/journal.pone.0078726.g003
MLH1-Inducible Cancer Cell Line
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contains wild type MLH1 [28]. In other cancer types, such as in
lung cancer, MMR deficiency can be promoted by carcinogen
exposure [7-9]. Chemotherapy treatment also may promote
MMR deficiency leading to secondary leukemia [6]. The cell
line system we describe provides the first example of an
isogenic model for induced MMR deficiency that can be
reversibly switched on or off at the level of control of protein
expression. It provides a model to study questions about
Figure 4.  MLH1-deficient NCI-H23 cells display increased cell sensitivity to rhodium metalloinsertor compounds.  NCI-H23
subclones that were uninduced or induced for MLH1 shRNA were treated with the rhodium metalloinsertor compound [Rh(chrysi)
(phen)(DPE)]3+. (A) Cells were treated at concentrations indicated, and cell viability was assessed after 4d using a Cell Titer-Glo
assay. Percent viability of duplicate samples from a single experiment is shown. The p value was determined as p=0.01 by a t test.
(B) Phase contrast images of cells treated with 5 µM [Rh(chrysi)(phen)(DPE)]3+ at 0h and 96h during the cell viability assay are
shown. (C) Cells were treated with [Rh(chrysi)(phen)(DPE)]3+ for 24h, and then assayed for colony formation after 10d. The graphs
show percent survival of duplicate samples of compound treated cells. The p value was determined as p=0.01 by a t test.
doi: 10.1371/journal.pone.0078726.g004
MLH1-Inducible Cancer Cell Line
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induced MMR deficiency and to allow identification of
molecules that might offer therapeutic benefit in MMR-deficient
cancers.
The NCI-H23 matched cell line system described here
permits detailed characterization of the timing and sequence of
events that result when MMR deficiency is induced. We
observed similar effects with three different shRNA sequences
targeted to MLH1, and in two different single cell subclones
isolated from cells transduced with one of the MLH1 shRNA
constructs. ShRNA-mediated inhibition of MLH1 expression is
an early event in induced MMR deficiency, with MLH1 protein
levels nearly undetectable by 3d. In contrast, the genomic
alterations resulting from MLH1 loss of function in cells (for
example, MSI) were not observed until several additional
weeks in culture. Consistent with reports that MMR deficiency
may lead to mutation of different target genes in different
individuals or cancer types [12,13,29], we found that
independent cell subclones displayed MSI at different
molecular markers. Re-expression of MLH1 by growth of the
subclones in the absence of doxycycline restores MMR
function and provides the possibility that re-activation of the
MMR pathway in cancer cells can also be investigated using
this cell line system. Further studies with the inducible NCI-H23
subclones may facilitate understanding of drug response and
resistance in MMR-deficient cancer cells.
Our system is complementary to matched cell line systems
commonly used to study MMR, such as the MMR-deficient
cancer cell lines HCT-116 or Hec59, which are complemented
by an extra copy of the chromosome containing wild type
MLH1 or MSH2, respectively [28,30]. In these models, the
MMR-proficient cells and MMR-deficient cells are generated as
different clones, and are chromosomally distinct from each
other and the parental cell line. These differences may result in
changes in chromosome stability or gene expression that are
not solely due to MMR deficiency [31,32]. Matched normal cell
systems, such as MMR-deficient embryonic kidney cells 293T
compared to 293T cells engineered to overexpress MLH1 [33],
or wild-type mouse embryonic fibroblasts (MEFs) compared to
MSH2-deficient MEFs [34] may be not be ideal models to study
MMR function in cancer. MEFs may be less sensitive to defects
in DNA repair than cancer cells, and have been reported to
exhibit a much lower mutation rate than MMR-deficient cancer
cells [31,35].
There is currently no targeted therapy for patients with MMR-
deficient cancer. The standard of care for patients with
colorectal cancer remains adjuvant combined chemotherapy
that includes the nucleoside inhibitor 5-FU, even though
multiple clinical studies have now shown that MMR-deficient
tumors might not benefit from 5-FU treatment (reviewed in
4,27). In addition to defects in DNA damage recognition and
repair [11], MMR-deficient colorectal tumors display distinct
features such as localization to the proximal colon, decreased
metastasis, increased number of tumor infiltrating lymphocytes,
and near-diploid DNA content of the cells [36]. These
characteristics may contribute to the better overall prognosis
reported for patients with MMR-deficient colorectal cancer
when compared on a stage by stage basis to patients with
MMR-proficient cancers [37]. However, there is still a need for
therapeutics that will be efficacious in MMR-deficient tumors.
Synthetic lethality screens have identified several potential
therapeutic targets for MMR-deficient cancer cells.
Methotrexate, an inhibitor of dihydrofolate reductase, was
reported to show synthetic lethality in MSH2-deficient cancer
cells [38] and is currently in clinical trials for MSH2-deficient
colorectal cancer (www.clinicaltrials.gov; Identifier:
NCT00952016). Inhibition of DNA polymerases, POLB or
POLG, caused synthetic sickness or synthetic lethality in
cancer cells deficient for MSH2 or MLH1, respectively [38].
MMR-deficient colorectal cancer cells were also reported to be
preferentially sensitive to inhibitors of cytosine-based
nucleoside analogs such as cytarabine [39], the PI3
kinase/AKT pathway [40], and the PTEN-induced putative
kinase PINK1 [41]. A disadvantage of the synthetically lethal
interactions identified is that in several cases, these appear to
be specific for a single gene mutation and may not apply to
targets in other pathways. It remains to be determined whether
the proposed mechanistic basis for these synthetically lethal
interactions will translate to efficacy in patients with genotypic
and phenotypic tumor heterogeneity.
We previously considered targeting the end “state” of
genomic instability [15]. We have demonstrated that rhodium
metalloinsertor compounds can bind DNA mismatches and
preferentially inhibit the proliferation of MMR-deficient cells,
including the MLH1-deficient HCT-116 colorectal cancer cell
line [16,19,21]. Here we confirm and extend our previous
observations by demonstrating, in a completely isogenic
system, preferential sensitivity of cells induced for MMR
deficiency to rhodium metalloinsertor compounds. The
differential activity of the compounds in MMR-deficient cells
correlates with their binding affinity to DNA mismatches in vitro
[19]. Recently, the differential cellular activity of these
compounds has also been shown to correlate with their
accumulation in the cell nucleus [21]. Together, these
observations support the model that rhodium metalloinsertor
compounds act directly on DNA mismatches in genomic DNA.
The metal complexes enter cells by passive diffusion and bind
non-covalently to mismatched DNA due to the thermodynamic
destabilization of mispaired nucleosides (reviewed in 42). This
mechanism of mismatched base pair recognition is distinct
from the checkpoint surveillance process normally used by
cells which involves proteins associated with the replication
fork during S phase [43]. MMR-deficient cells show a 100- to
1000-fold increase in spontaneous mutation rate (1 X 10-6 to 1
X 10-8) compared to that of MMR-proficient cells which is
estimated at 1 X 10-9 to 1 X 10-10 per replicated base pair
(reviewed in 44,45). It is provocative that the rhodium
metalloinsertor compounds have the ability to recognize this
number of DNA mismatches, and differentially inhibit the
proliferation of MMR-deficient cells in vitro, in the context of
approximately 6 billion correctly paired bases. We speculate
that this differential effect may translate to even greater
therapeutic benefit in vivo.
It is striking that the MLH1-deficient cells, which show
increased resistance to DNA damaging agents, are
preferentially sensitive to rhodium metalloinsertor compounds.
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We have observed differential effects for this class of
compounds consistently across multiple experiments and in
different assays for cell proliferation. The differential effect on
cell proliferation observed with the rhodium metalloinsertor
compounds cannot be explained simply by the growth rate of
the MLH1-deficient NCI-H23 subclones, which is similar for the
MLH1-proficient and the MLH1-deficient cells. We do not yet
understand the molecular mechanism of the preferential
sensitivity of MMR-deficient cells to rhodium metalloinsertor
compounds. The compounds might interfere with cellular DNA
replication or transcription. The replication fork may not be able
to synthesize through mismatched DNA bound with a metal
complex However, the metal complexes bind noncovalently to
mismatched DNA, suggesting that the compounds may
dissociate during the DNA unwinding that occurs during
replication. Alternatively, the compounds might associate with
proteins adjacent to a DNA mismatch. Current studies are
focused on addressing these hypotheses, and also on
improving the potency and drug-like properties of the current
series of rhodium metalloinsertor compounds for applications in
cancer therapy.
Supporting Information
Figure S1.  Multiple, independent MLH1 shRNA constructs
can downregulate MLH1 protein. NCI-H23 cells were
transduced with 4 independent shRNA constructs against
MLH1 or MSH2 and then maintained with the shRNA
uninduced (-), or treated with 1 µg/ml doxycycline to induce
shRNA expression (+). Protein lysates were analyzed by SDS-
PAGE and immunoblotting for (A) MLH1 or (B) MSH2 protein.
Tubulin levels were used as a control for equal protein loading
across samples.
(TIF)
Figure S2.  Single cell subclones with MLH1 shRNA
induced exhibit microsatellite instability. Genomic DNA was
prepared from MLH1-deficient NCI-H23 subclones and NCI-
H23 parental cells (H23) and used in multiplex PCR for 5
standard markers of MSI. MSI was determined by fragment
analysis. Clones 4-10 and 4-13 displayed microsatellite
instability at the BAT-26 marker. Clone 4-10 also displayed
possible microsatellite instability at the NR-21 marker, while
clone 4-13 showed possible instability at the MONO-27 and
NR-21 markers. Each clone was analyzed at least twice in
independent experiments; representative data from a single
experiment are shown.
(TIF)
Figure S3.  Microarray analysis of NCI-H23 subclones.
Total RNA from NCI-H23 subclones grown under uninducing or
inducing conditions was labeled and hybridized to whole
genome arrays. The gene expression data was exported to
Rosetta Resolver and trends compared between the uninduced
and induced samples and between the different subclones. The
graph shows a comparison of the changes in gene expression
for the 4-10 subclone versus (vs.) the 4-13 subclone. Genes
with no change in expression level between the subclones are
marked in blue. The MLH1 gene, which showed a three-fold
decrease in expression in the MLH1-deficient subclones, is
indicated in red text.
(TIF)
Figure S4.  Uninduced NCI-H23 subclones show similar
sensitivity to etoposide as the parental cells. NCI-H23
subclones that were uninduced (- Dox) were compared to
parental NCI-H23 cells grown in the presence (+ Dox) or
absence (- Dox) of doxycycline. Cells were treated at
concentrations indicated, and cell viability was assessed after
4d using a Cell Titer-Glo assay. Percent viability of single
samples from a representative experiment is shown.
Comparison of the IC50 values by t test determined that p=0.34.
(TIF)
Figure S5.  MLH1-deficient NCI-H23 subclones display
increased resistance to DNA-damaging drugs. NCI-H23
subclones that were uninduced or induced for MLH1 shRNA
were treated with (A) cisplatin, (B) 6-thioguanine or (C)
doxorubicin as indicated, and then cell viability was assessed
after 4d using a Cell Titer-Glo assay. The graphs indicate the
relative survival for duplicate samples from a single
experiment. T tests determined the p values as p=0.02, p=0.05
and p=0.04, respectively, for cells treated with cisplatin, 6-
thioguanine or doxorubicin.
(TIF)
Figure S6.  Independent MLH1 shRNA constructs confer
differential sensitivity to etoposide. NCI-H23 cells
transduced with (A) MLH1 shRNA 362 or (B) MLH1 shRNA
2239 were divided into two cultures, and grown in conditions
that were uninduced (MLH1-proficient) or induced for MLH1
shRNA (MLH1-deficient). The cells were treated with etoposide
and cell viability was assessed after 4d using a Cell Titer-Glo
assay. Percent viability of duplicate samples from a
representative experiment is shown. The p value was
determined as p=0.01 by t test.
(TIF)
Figure S7.  Etoposide treatment induces apoptosis in
MMR-proficient NCI-H23 subclones. MLH1-proficient and
MLH1-deficient NCI-H23 subclones were treated with 10 µM
etoposide for 24h, and then levels of phosphorylated histone
H2AX (Phospho-H2AX), a marker for apoptosis, were
assessed. MLH1 protein is shown to confirm the cells are
MMR-proficient or MMR-deficient. Tubulin levels are shown as
a control for protein loading.
(TIF)
Figure S8.  Sensitivity of NCI-H23 subclones to additional
rhodium metalloinsertor compounds. (A) Chemical structure
of [Rh(HDPA)2chrysi]3+. (B) NCI-H23 subclones that were
uninduced or induced for MLH1 shRNA were treated with
[Rh(HDPA)2chrysi]3+ as indicated, and cell viability was
assessed after 4d using a Cell Titer-Glo assay. A t test
determined the p value to be p=0.02. (C) Chemical structure of
[Rh(DIP)2chrysi]3+. (D) NCI-H23 subclones that were uninduced
MLH1-Inducible Cancer Cell Line
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or induced for MLH1 shRNA were treated with
[Rh(DIP)2chrysi]3+ as indicated, and cell viability was assessed
after 4d using a Cell Titer-Glo assay. Percent viability from
duplicate samples of a single experiment is shown. A t test
determined the p value to be p=0.90.
(TIF)
Figure S9.  Independent MLH1 shRNA constructs cause
preferential sensitivity to rhodium metalloinsertor
compounds. NCI-H23 cells transduced with MLH1 shRNA 362
or MLH1 shRNA 2239 were divided into two cultures, and
grown in conditions that were uninduced (MLH1-proficient) or
induced for MLH1 shRNA (MLH1-deficient). Cells were treated
with (A) [Rh(DPE)(phen)chrysi]3+ or (B) [Rh(HDPA)2chrysi]3+
and cell viability was assessed after 4d using a Cell Titer-Glo
assay. Percent viability from duplicate samples of a single
experiment is shown. The p value was determined as p=0.01
by t test.
(TIF)
Figure S10.  Treatment of NCI-H23 subclones with rhodium
metalloinsertor compounds does not alter MSI status.
MLH1-proficient and MLH1-deficient NCI-H23 subclones were
treated with 5uM [Rh(DPE)(phen)chrysi]3+ for 24h, and then
protein lysates were prepared and analyzed for MLH1 protein
levels as a marker for MSI. Levels of tubulin were also
assessed as a control for protein loading.
(TIF)
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